Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL1B | P01584 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25533187 | 1.00 | DDB1 (0.58) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20466159 | 0.89 | DDB1 (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20317527 | 0.85 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21763559 | 0.85 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL17277066 | 0.84 | DDB1 (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25848032 | 0.83 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23707575 | 0.82 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL13464196 | 0.81 | CRBN (0.57) | DDB1CRBNSTAT3 | |
| SCHEMBL13622224 | 0.81 | CRBN (0.56) | DDB1CRBNSTAT3 | |
| SCHEMBL29315551 | 0.80 | DDB1 (0.58) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-18 | — | — | US | disclosed |
| US-20230159593-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | BRIX1, TP53, XPOT | DDB1 614/4885CRBN 580/4885IKZF3 1225/4885 |
| US-20230159593-A1 | CYCLOSPORINE ANALOGUES | HAVCR2, CHP1, HLA-C | DDB1 1997/4885CRBN 2642/4885IKZF3 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.